3.8 Meeting Abstract

Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49

Journal

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
Volume 18, Issue -, Pages 233-234

Publisher

WILEY

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available